FDA's approval will allow Kedrion to manufacture Ryplazim (plasminogen, human-tvmh), the only FDA-approved therapy for treating PLGD-1, at facility in Bolognana, Italy.
Nicholas Saraceno
Advertisement
Nicholas Saraceno is editor at Pharmaceutical Commerce.
Articles by Nicholas Saraceno
The Thousand Oaks, Calif., cell therapy manufacturing facility now houses new production suites, updated development labs, and more after expansion.
The $3.6 million investment will allow the CDMO to boost its advanced labeling, automated visual inspection, and fill/finish capabilities.
Advertisement
Latest Updated Articles
Pii Boosts Prefilled Syringe Capabilities with $3.6 Million InvestmentPublished: November 23rd 2024 | Updated:
FDA Grants Approval to Kedrion to Produce PLGD-1 Therapeutic at Bolognana PlantPublished: November 23rd 2024 | Updated:
- Fujifilm's Cell Therapy Facility Expansion Completed
Published: November 23rd 2024 | Updated:
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
CPHI 2025 Awards Spotlight Breakthroughs in Pharmaceutical Manufacturing and API Development
2
AI and Human Collaboration Essential for Bio/pharma Innovation
3
Sustainability and Stability in Excipients
4
Centralizing AI Strategy, Ensuring Process Integrity, and Balancing Quick Wins with Long-Term Drug Design in Bio/pharma
5
